GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Firebrick Pharma Ltd (ASX:FRE) » Definitions » Return-on-Tangible-Asset

Firebrick Pharma (ASX:FRE) Return-on-Tangible-Asset : -136.38% (As of Dec. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Firebrick Pharma Return-on-Tangible-Asset?

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Firebrick Pharma's annualized Net Income for the quarter that ended in Dec. 2024 was A$-2.89 Mil. Firebrick Pharma's average total tangible assets for the quarter that ended in Dec. 2024 was A$2.12 Mil. Therefore, Firebrick Pharma's annualized Return-on-Tangible-Asset for the quarter that ended in Dec. 2024 was -136.38%.

The historical rank and industry rank for Firebrick Pharma's Return-on-Tangible-Asset or its related term are showing as below:

ASX:FRE' s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -116.16   Med: -43.65   Max: -37.04
Current: -83.56

During the past 4 years, Firebrick Pharma's highest Return-on-Tangible-Asset was -37.04%. The lowest was -116.16%. And the median was -43.65%.

ASX:FRE's Return-on-Tangible-Asset is ranked worse than
91.58% of 1021 companies
in the Drug Manufacturers industry
Industry Median: 2.68 vs ASX:FRE: -83.56

Firebrick Pharma Return-on-Tangible-Asset Historical Data

The historical data trend for Firebrick Pharma's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Firebrick Pharma Return-on-Tangible-Asset Chart

Firebrick Pharma Annual Data
Trend Jun21 Jun22 Jun23 Jun24
Return-on-Tangible-Asset
- -37.04 -116.16 -43.65

Firebrick Pharma Semi-Annual Data
Jun21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Return-on-Tangible-Asset Get a 7-Day Free Trial -87.28 -170.56 -72.90 -25.47 -136.38

Competitive Comparison of Firebrick Pharma's Return-on-Tangible-Asset

For the Drug Manufacturers - General subindustry, Firebrick Pharma's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Firebrick Pharma's Return-on-Tangible-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Firebrick Pharma's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where Firebrick Pharma's Return-on-Tangible-Asset falls into.


;
;

Firebrick Pharma Return-on-Tangible-Asset Calculation

Firebrick Pharma's annualized Return-on-Tangible-Asset for the fiscal year that ended in Jun. 2024 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: Jun. 2024 )  (A: Jun. 2023 )(A: Jun. 2024 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: Jun. 2024 )  (A: Jun. 2023 )(A: Jun. 2024 )
=-1.176/( (2.982+2.406)/ 2 )
=-1.176/2.694
=-43.65 %

Firebrick Pharma's annualized Return-on-Tangible-Asset for the quarter that ended in Dec. 2024 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: Dec. 2024 )  (Q: Jun. 2024 )(Q: Dec. 2024 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: Dec. 2024 )  (Q: Jun. 2024 )(Q: Dec. 2024 )
=-2.892/( (2.406+1.835)/ 2 )
=-2.892/2.1205
=-136.38 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is two times the semi-annual (Dec. 2024) net income data.


Firebrick Pharma  (ASX:FRE) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


Firebrick Pharma Return-on-Tangible-Asset Related Terms

Thank you for viewing the detailed overview of Firebrick Pharma's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Firebrick Pharma Business Description

Traded in Other Exchanges
N/A
Address
440 Collins Street, Level 10, Melbourne, VIC, AUS, 3000
Firebrick Pharma Ltd is an Australian pharmaceutical developer. It is engaged in the development and commercialization of povidone-iodine (PVP-I) products under the Nasodine brand. Its Nasodine Nasal Spray which is in the commercialization phase, is a broad-spectrum anti-viral spray, designed to be an effective treatment and prevention of respiratory viral infections such as the common cold. In parallel, the company is also engaged in the development of the follow-on Nasodine brand products.

Firebrick Pharma Headlines

No Headlines